AIM ImmunoTech Inc. (AIM) Social Stream

Featured Post From StockTwits About AIM

$AIM interesting that they are doing 5 doses (potentially 6 if they add a booster but CRO doesnt think they will need it which must be based on their review of the P1 data) in the human challenge study instead of the 7 doses they did in the P1 intranasal study. Also no mention of different dosage strengths in the human challenge study. So in the P1 Intranasal Study they must have identified the optimal dosage strength and number of doses to generate the best response. Seeing this protocol leads me to continue to believe the P1 data is positive and that they have all the data and we should have it soon.